These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30381896)

  • 1. A novel antibody combination to identify KIR2DS2
    Blunt MD; Rettman P; Bastidas-Legarda LY; Fulton R; Capizzuto V; Naiyer MM; Traherne JA; Khakoo SI
    HLA; 2019 Jan; 93(1):32-35. PubMed ID: 30381896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.
    David G; Djaoud Z; Willem C; Legrand N; Rettman P; Gagne K; Cesbron A; Retière C
    J Immunol; 2013 Nov; 191(9):4778-88. PubMed ID: 24078689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
    Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphasic response of NK cells expressing both activating and inhibitory killer Ig-like receptors.
    Warren HS; Campbell AJ; Waldron JC; Lanier LL
    Int Immunol; 2001 Aug; 13(8):1043-52. PubMed ID: 11470774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals.
    Legrand N; David G; Rodallec A; Gaultier A; Salmon D; Cesbron A; Wittkop L; Raffi F; Gendzekhadze K; Retière C; Allavena C; Gagne K
    Clin Exp Immunol; 2021 Apr; 204(1):107-124. PubMed ID: 33314121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantity of HLA-C surface expression and licensing of KIR2DL+ natural killer cells.
    Charoudeh HN; Schmied L; Gonzalez A; Terszowski G; Czaja K; Schmitter K; Infanti L; Buser A; Stern M
    Immunogenetics; 2012 Oct; 64(10):739-45. PubMed ID: 22772778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.
    Frazier WR; Steiner N; Hou L; Dakshanamurthy S; Hurley CK
    J Immunol; 2013 Jun; 190(12):6198-208. PubMed ID: 23686481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies.
    David G; Morvan M; Gagne K; Kerdudou N; Willem C; Devys A; Bonneville M; Folléa G; Bignon JD; Retière C
    Immunology; 2009 Oct; 128(2):172-84. PubMed ID: 19740374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
    Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
    Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide selectivity discriminates NK cells from KIR2DL2- and KIR2DL3-positive individuals.
    Cassidy S; Mukherjee S; Myint TM; Mbiribindi B; North H; Traherne J; Mulder A; Claas FH; Purbhoo MA; Das J; Khakoo SI
    Eur J Immunol; 2015 Feb; 45(2):492-500. PubMed ID: 25359276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
    Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of a novel KIR2DL3-specific mAb: comparative analysis of the surface distribution and function of KIR2DL2, KIR2DL3 and KIR2DS2.
    Vitale M; Carlomagno S; Falco M; Pende D; Romeo E; Rivera P; Della Chiesa M; Mavilio D; Moretta A
    Int Immunol; 2004 Oct; 16(10):1459-66. PubMed ID: 15314042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined genotypic and phenotypic killer cell Ig-like receptor analyses reveal KIR2DL3 alleles displaying unexpected monoclonal antibody reactivity: identification of the amino acid residues critical for staining.
    Falco M; Romeo E; Marcenaro S; Martini S; Vitale M; Bottino C; Mingari MC; Moretta L; Moretta A; Pende D
    J Immunol; 2010 Jul; 185(1):433-41. PubMed ID: 20525888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Activating Human NK Cell Receptor KIR2DS2 Recognizes a β
    Thiruchelvam-Kyle L; Hoelsbrekken SE; Saether PC; Bjørnsen EG; Pende D; Fossum S; Daws MR; Dissen E
    J Immunol; 2017 Apr; 198(7):2556-2567. PubMed ID: 28202613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
    Askar M; Avery R; Corey R; Lopez R; Thomas D; Pidwell D; Eghtesad B; Miller C; Fung J; Zein NN
    Liver Transpl; 2009 Nov; 15(11):1557-63. PubMed ID: 19877200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell receptor variants and chronic hepatitis B virus infection in the Vietnamese population.
    Auer ED; Tong HV; Amorim LM; Malheiros D; Hoan NX; Issler HC; Petzl-Erler ML; Beltrame MH; Boldt ABW; Toan NL; Song LH; Velavan TP; Augusto DG
    Int J Infect Dis; 2020 Jul; 96():541-547. PubMed ID: 32422377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of demethylation treatment on the expression of inhibitory receptor KIR gene in NK-92MI cell line].
    Gao XN; Lin J; Wang LL; Gao L; Jin HJ; Sun JF; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):656-60. PubMed ID: 19549382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.
    Hilton HG; Guethlein LA; Goyos A; Nemat-Gorgani N; Bushnell DA; Norman PJ; Parham P
    J Immunol; 2015 Oct; 195(7):3160-70. PubMed ID: 26311903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of killer cell immunoglobulin- like receptor genes with rheumatoid arthritis.
    Ramírez-De los Santos S; Sánchez-Hernández PE; Muñoz-Valle JF; Palafox-Sánchez CA; Rosales-Rivera LY; García-Iglesias T; Daneri-Navarro A; Ramírez-Dueñas MG
    Dis Markers; 2012; 33(4):201-6. PubMed ID: 22960345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.